- Home
- CTMX vs THTX Comparison
CTMX vs THTX Comparison
Compare CTMX & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- THTX
- Stock Information
- Founded
- CTMX 2008
- THTX 1993
- Country
- CTMX United States
- THTX Canada
- Employees
- CTMX N/A
- THTX N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- THTX Health Care
- Exchange
- CTMX Nasdaq
- THTX Nasdaq
- Market Cap
- CTMX 62.3M
- THTX N/A
- IPO Year
- CTMX 2015
- THTX N/A
- Fundamental
- Price
- CTMX $0.58
- THTX $1.40
- Analyst Decision
- CTMX Buy
- THTX Hold
- Analyst Count
- CTMX 6
- THTX 1
- Target Price
- CTMX $5.77
- THTX N/A
- AVG Volume (30 Days)
- CTMX 3.8M
- THTX 3.0M
- Earning Date
- CTMX 03-06-2025
- THTX 04-09-2025
- Dividend Yield
- CTMX N/A
- THTX N/A
- EPS Growth
- CTMX N/A
- THTX N/A
- EPS
- CTMX 0.38
- THTX N/A
- Revenue
- CTMX $138,103,000.00
- THTX $85,866,000.00
- Revenue This Year
- CTMX N/A
- THTX $3.57
- Revenue Next Year
- CTMX N/A
- THTX $7.73
- P/E Ratio
- CTMX $1.57
- THTX N/A
- Revenue Growth
- CTMX 36.45
- THTX 5.02
- 52 Week Low
- CTMX $0.56
- THTX $1.08
- 52 Week High
- CTMX $5.85
- THTX $2.18
- Technical
- Relative Strength Index (RSI)
- CTMX 37.64
- THTX 40.24
- Support Level
- CTMX $0.57
- THTX $1.31
- Resistance Level
- CTMX $0.65
- THTX $2.12
- Average True Range (ATR)
- CTMX 0.05
- THTX 0.13
- MACD
- CTMX 0.00
- THTX -0.01
- Stochastic Oscillator
- CTMX 15.04
- THTX 11.11
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.